

Special Issue

MicroRNA in Solid Tumor and Hematological Diseases 2.0

Message from the Guest Editor

MicroRNAs (miRNAs), short non-coding RNA, are involved in physiologic and pathologic processes. MiRNAs play a key role in cancer pathogenesis by inhibiting gene expression at the post-transcriptional level. Moreover, miRNAs are differentially expressed in tumors compared to normal human tissues and they can be divided into oncomiRNAs and tumor suppressor miRNAs, although some miRNAs can act both roles depending on the cellular context. As a potential therapeutic approach for cancer, extensive studies have demonstrated how to deregulate the small non-coding transcriptome, whether down-regulating the expression of oncogenic miRNAs or overexpressing tumor-suppressive miRNAs. Therefore, the accurate analysis of miRNAs expression from cancer patients might be a useful tool to develop personalized medicine in the future.

This Special Issue will focus on the role of miRNAs in controlling pivotal biological mechanisms that lead to oncogenic transformation and tumor formation, growth, and dissemination, as well as their diagnostic and prognostic significance in different cancer subtypes. Original research manuscripts and comprehensive reviews are both welcome for this call.

Guest Editor

Dr. Francesca Lovat

Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA

Deadline for manuscript submissions

closed (15 May 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/84242

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).